EMA Authorised: Tresiba (insulin degludec) — Novo Nordisk A/S

View source ↗

Summary

The EMA authorised Tresiba (insulin degludec) for use in diabetes mellitus in the European Union. Novo Nordisk A/S is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Tresiba (insulin degludec)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 26/06/2025